| CPC C07K 14/4748 (2013.01) [A61K 39/0011 (2013.01); A61K 39/001162 (2018.08); A61K 39/00117 (2018.08); A61K 39/001176 (2018.08); A61K 39/001182 (2018.08); A61K 39/001188 (2018.08); C07K 7/06 (2013.01); C07K 7/08 (2013.01); G01N 33/57419 (2013.01); G01N 33/57449 (2013.01); G01N 33/57496 (2013.01); G01N 2333/47 (2013.01); G01N 2333/978 (2013.01); G01N 2440/18 (2013.01); G01N 2800/52 (2013.01)] | 12 Claims |
|
1. A method of treating cancer in a subject identified as having MHC class II expressing tumor cells undergoing autophagy, wherein the autophagy comprises peptidylarginine deiminase 2 (PAD2) or peptidylarginine deiminase 4 (PAD4) enzyme-mediated production of self-epitopes having a modification of deimination of arginine to citrulline, wherein the resulting self-epitopes are presented on the surface of the tumor cells via MHC class II complexes, the method comprising administering to the subject a composition that comprises a Th1 adjuvant and peptides comprising at least one of the self-epitopes in an amount effective to induce IFN-γ and granzyme B-secreting CD4 T-cells that bind the MHC class II complexes presented on the surface of the tumor cells.
|